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identify signiﬁ cant potential determinants. RESULTS: The decision of vaccination for 
inﬂ uenza virus H1N1 was associated with factors related to education, income, inter-
action between education and income, gender, trust to Public Health Organizations 
and perceptions about the health effects of inﬂ uenza virus H1N1. Individuals of higher 
education and income, do not intend to get vaccinated. This also holds for individuals 
who express low degree of trust to or believe that the H1N1 virus is not a serious 
threat to human health. CONCLUSIONS: We identiﬁ ed several socioeconomic and 
demographic factors affecting individual intent to get vaccinated for H1N1. Personal 
beliefs about the health effects of H1N1 virus and trust to Public Health Organizations 
were also signiﬁ cant predictors of vaccination intent.
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PARENTS’ DILEMMA WHETHER OR NOT TO VACCINATE THEIR 
CHILDREN AGAINST INFLUENZA A (H1N1)
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OBJECTIVES: In April 2009, WHO announced the emergence of Inﬂ uenza a (H1N1) 
and a phase 6 pandemic was declared a few months later. Vaccination was identiﬁ ed 
as an effective measure in order to eliminate the pandemic and ensure public health. 
The aim of the present study was to investigate the factors affecting parents’ decision 
to vaccinate their children. METHODS: A telephone survey was conducted in a random 
sample of 12,639 households stratiﬁ ed by geographical area using a strictly structured 
questionnaire designed for the purpose of the study. The survey lasted from October 
2009 to January 2010. a logistic regression analysis was conducted in order to identify 
the factors that inﬂ uence parents’ decision to vaccinate their children. The Hosmer–Lem-
eshow criterion was used to check the model’s goodness of ﬁ t. RESULTS: A total of 
3585 households were eligible and were included in the analysis. Education, income, 
concern about H1N1 and trust to the CDC were statistically signiﬁ cant. According to 
the analysis the higher the levels of education (OR 0.64) and income (OR 0.80) of the 
parents the lower the probability to vaccinate their children. However, the interaction 
term between education and income showed a positive relationship between these and 
the dependent variable. The greater the concern about H1N1 and the trust to the CDC 
the higher the probability for the parents to vaccinate their children. The Hosmer–Lem-
eshow goodness of ﬁ t test statistic was 0.52 suggesting satisfactory ﬁ t of the model. 
CONCLUSIONS: Based on our results concerns about the H1N1 and trust on the CDC 
were inﬂ uencing positively the decision for vaccination. The negative relationship 
between education and income and parents’ decision for vaccination was interesting and 
need further investigation. Results can explain the low vaccination rates against H1N1 
in Greece and can be used by policy makers to improve future vaccination campaigns.
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OBJECTIVES: Determine the number of patients who received antiretroviral therapy 
(ART) potentially prescribed for prevention of HIV infection in Germany in 2008. 
METHODS: A representative panel of 1,193,464 patients from different nationwide 
operating governmental sick funds were analyzed for 2008. Patients with a conﬁ rmed 
diagnosis of HIV (ICD-10: B20–24: 64,8%; R75: 0,9%; U85: 0,6%; U60–61: 14,9%; 
Z21: 18,8%) were included. In addition, an IMS pharmacy panel (LRx) with 26,815 
patients who had received ART identiﬁ ed by ATC Code J05C (Tenofovir was excluded 
because of use in Hepatitis) in October 2008 to September 2009 were analyzed (54% 
of all patients with ART-prescriptions). RESULTS: Sick funds: 927 patients with HIV 
diagnosis were identiﬁ ed (0.08% of the panel), 548 received an ART (treatment rate 
59.1%). Pharmacies: 46% of patients received an ART prescription in 4 quarters, 
16.9% in 3 quarters, 12.1% in 2 quarters and 24.9% in 1 quarter. 17.5% received 
prescriptions only on 1 day while of these patients 12% did not have any other ART 
prescription at least 4 months before or after the analysis period. Patients who received 
prescriptions on 1 day only, were younger, more often female and received more often 
Lopinavir/Ritonavir compared to patients who received prescriptions on more days. 
When extrapolating the numbers to the German governmentally insured population 
and comparing the numbers from sick funds of patients with a conﬁ rmed diagnosis 
receiving ART with patients who received an ART from pharmacies, about 30% of 
patients with ART prescription could not be matched to a conﬁ rmed diagnosis. 
CONCLUSIONS: Thirty percent of patients received ART prescriptions without con-
ﬁ rmed HIV diagnosis. Twelve percent of patients received ART prescriptions on one 
day only. Since these patients were younger, more often female and received agents 
more often used in prophylactic regimens, we assume that prescription of ART for 
prevention or post-exposure prophylaxis is likely in this group.
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THE USE OF ECONOMIC ANALYSIS IN VACCINE EXPERT REVIEWS
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OBJECTIVES: Since the beginning of the new millennium, prices of vaccines have 
been increasing signiﬁ cantly, reﬂ ecting decades of research and development. As they 
have done with pharmaceuticals, governments have begun to incorporate economic 
considerations into scientiﬁ c reviews. Vaccines fall into the public health category, 
whose ethic differs historically from that in the pharmaceutical market. The purpose 
of this paper is to review how countries have incorporated economics into the scientiﬁ c 
vaccine review process. METHODS: We contacted experts in countries which had 
scientiﬁ c review committees according to the VENICE website, and the USA, Austra-
lia, New Zealand, and Hong Kong. We asked a series of questions regarding the 
structure of the review process, the role of economics, and the economic criteria used. 
RESULTS: We obtained information from ten countries which used economics in their 
vaccine scientiﬁ c reviews. In terms of structure, reviews fell into two groups—those 
which incorporated economics into the scientiﬁ c review (GB, FI, FR, HK, NL, NZ, US) 
and those which separated economic and clinical considerations (SW, AU). The criteria 
used in economic studies followed the pharmaceutical guidelines in all instances. CON-
CLUSIONS: Pharmaco-economics has grown up in the world of pharmaceuticals, not 
in the public health arena. The ethics in these two arenas differ. Certain elements—epi-
demiological considerations, herd immunity, long effect times—are relevant to vaccines. 
Using pharmacoeconomic rules for vaccines may not create a level playing ﬁ eld. 
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VACCINATION OVER TIME?
Standaert B1, Gomez J2, Acosta-Rodriguez C3, Debrus S1
1GlaxoSmithKline Biologicals, Wavre, Belgium; 2GlaxoSmithKline Biologicals, Buenos Aires, 
Argentina; 3GlaxoSmithKline, Philadelphia, PA, USA
OBJECTIVES: Models estimating the impact of rotavirus vaccines over time use 
vaccine efﬁ cacy (VE) results from clinical trials measured at different time points. The 
formula to calculate VE measures diarrhea events observed in the vaccinated arm 
divided by events in the non-vaccinated arm during certain periods. Two problems 
occur: 1) the control arm builds up its own natural immunity over time: VE measured 
by the formula is therefore the net vaccine effect (NVE) that decreases as soon as the 
rate of infection increases; 2) natural immunity should be considered in the vaccinated 
arm as well as a booster phenomenon whereas this is generally omitted. How much 
will the cost-effectiveness result be impacted if natural immunity in the vaccinated arm 
is considered by improving the NVE-value over time? METHODS: A markov cohort 
model is used to measure the cost-effectiveness of vaccinating children at 2 and 3 
months against rotavirus infection in a country such as Panama as an example. The 
HE-model considers the health authority perspective, a life time horizon, and an 
annual discount rate of 3% on cost and effect. In sensitivity analysis the NVE decrease 
is varied over time post-vaccination from an annual linear 15% decrease to equal 
value post-2 doses. The outcome measure is the change in cost-effectiveness result in 
function of the variation in NVE-decrease. RESULTS: With the 15% decrease in NVE 
the QALY gain is 0.0124/person, the extra cost $2.46, and the ICER = $199/QALY 
gained. Improving the NVE to no decrease post-2 doses results in a QALY gain of 
0.0132 (+6%), an extra-cost of $0.98 (−99%), and an ICER reduction to $74/QALY 
gained. CONCLUSIONS: Assuming sustained VE over time because of natural immu-
nity in the vaccinated arm improves the economic results -especially the costs data. 
The gain will mainly occur post-disease peak after 2 years.
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OBJECTIVES: Infectious diseases spread through social contacts and affect people of 
all age groups. Traditional epidemic models consider these effects with the use of 
differential equations, contact networks or explicit modelling of households and 
workplaces. However past modelling studies did not implement structures of the 
health service system, like service providers (e.g. physicians) and their reimbursement. 
Therefore we investigate the integration of an epidemic contact model for inﬂ uenza 
into a framework for modelling treatment pathways and reimbursement of service 
providers. METHODS: The model framework is of object-oriented and agent based 
type. It incorporates patients and providers as spatially distributed agents. When 
patients develop diseases they search for service providers and treatment through a 
central health market, which in general returns one of the nearest providers of 
requested type. Each disease is connected to the possible treatment pathways and 
health services that a patient with the speciﬁ c disease will go through. In the study we 
incorporate inﬂ uenza epidemics occurring at speciﬁ ed time intervals. These epidemics 
spread through contacts of the agents modelled by a small-world network. Patients 
get immune after recovering and therefore one epidemic cannot infect them twice. The 
model calculates reimbursement from consumed health provider services and drugs. 
RESULTS: Modeled epidemics show the well-known behaviour of SIR-type models. 
Reduced capacity of service providers provokes that many patients do not consult 
them due to queuing effects. The model maps the development of costs over time 
plausibly. Different prescription probabilities of neuraminidase inhibitors inﬂ uence the 
course of the epidemic only marginally. CONCLUSIONS: The integration of epidemic 
models with models of health service processes and reimbursement can lead toward 
13th Euro Abstracts A445
a broader understanding of the inﬂ uence of epidemics on health care systems. It is 
possible to investigate feedback of health service structure changes and reimbursement 
decisions on prevalence and effects of infectious diseases.
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BACKGROUND: Because health care is highly insured in Europe, many discrete-
choice experiment (DCE) researchers have concerns about the feasibility of obtaining 
valid willingness-to-pay (WTP) estimates. OBJECTIVES: To test the validity of WTP 
estimates obtained from patient DCE data in 5 countries. METHODS: Adults with a 
self-reported physician diagnosis of hepatitis B in 4 European countries (France, 
Germany, Spain, and Italy) and Turkey completed a web-enabled, DCE. The survey 
presented patients with a series of 12 trade-off questions, each including a pair of 
hypothetical hepatitis-B treatments described by efﬁ cacy, two side-effect risks, weight 
of evidence, and cost. All the subjects saw cost levels of c0, c10, and c25. Half the 
subjects evaluated an additional cost level of c75 and half the subjects evaluated an 
additional cost level of c150 per month. RESULTS: 664 subjects completed the survey. 
About 15% of subjects refused to accept any tradeoffs between costs and outcome 
attributes, while the remainder perceived no signiﬁ cant difference between costs of c0 
and c10. The difference in importance weights between the highest cost levels in each 
treatment arm was signiﬁ cantly different (P < 0.000). The importance weight of one 
additional euro in cost of c25 or greater was negative, highly signiﬁ cant, and equal 
in both arms (p = <0.000). Compared to a treatment with 70% probability of achiev-
ing no detectable virus after 5 years and no side-effect risk, the increase in value to 
patients of a hypothetical treatment that has 95% effectiveness, 1% 5-year fracture 
risk, and 1% 5-year risk of kidney disease is an additional c34 (c17–c51) per month. 
CONCLUSIONS: We obtained DCE responses in a split-sample test of cost sensitivity 
that were consistent with theoretical requirements. Results suggest that it is possible 
to obtain valid WTP estimates in a properly motivated European DCE. 
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REVIEW AND META-ANALYSIS
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OBJECTIVES: Behavioral and psychological symptoms of dementia (BPSD) in 
Alzheimer’s disease (AD) greatly increase caregiver burden and often trigger nursing 
home placement. a systematic review of double-blind randomized controlled trials 
(RCTs) was conducted to compare the ability of donepezil and memantine to manage 
BPSD in AD. METHODS: MEDLINE, EMBASE, Cochrane Library, and hand 
searches identiﬁ ed 4739 citations, of which 16 studies had Neuropsychiatric Inventory 
(NPI) data suitable for meta-analysis (6 memantine and ten donepezil trials). All trials 
were placebo-controlled, and no head-to-head comparisons of the two drugs were 
identiﬁ ed. a random-effects meta-analysis was conducted using AD severity subgroups 
to investigate heterogeneity between trials. Thereafter meta-regression was conducted 
using study level covariates as potential predictors of between-treatment weighted 
mean difference (WMD) in NPI score. RESULTS: Unadjusted random effects meta-
analysis of all 16 RCTs found signiﬁ cant between-study heterogeneity (all studies I2 = 
64.4%; donepezil vs. placebo WMD −1.84, 95%CI −3.57, −0.10, I2 = 61%; meman-
tine monotherapy vs. placebo WMD −1.19, 95% CI −3.70, 1.32, I2 = 68.7%; meman-
tine + AChEI combination therapy vs. placebo WMD −1.68 95% CI −5.70, 2.33, I2 
= 80.4%). Meta-regression that stratiﬁ ed studies into four AD severity groups mea-
sured by Mini-Mental State Exam (MMSE) (severe 0–9, moderately-severe 10–14, 
moderate 15–20 and mild 21–26) and controlling for age at baseline, found these 
covariates accounted for most (59.85%) of the between-study variance. Using this 
meta-regression model, the pooled NPI score for donepezil showed signiﬁ cant 
improvement compared to placebo (MD −1.50; 95% CI −2.63, −0.36) whereas this 
was not the case for memantine vs. placebo (MD −1.25; 95% CI −2.63, 0.13). CON-
CLUSIONS: Donepezil was associated with signiﬁ cant improvement in the manage-
ment of BPSD in AD patients compared to placebo, whereas memantine failed to show 
a signiﬁ cant improvement versus placebo in the management of these symptoms.
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DEPOT AND ORAL ANTIPSYCHOTICS IN MATCHED COHORTS OF 
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OBJECTIVES: To assess the all-cause medication discontinuation rate in matched 
cohorts of patients with schizophrenia at risk of nonadherence who were initiated on 
depot or oral antipsychotics and followed over 12 months. METHODS: At study 
entry, outpatients with schizophrenia from Australia, Mexico, Romania, and Taiwan 
were switched, due to clinician-perceived medication non-adherence risk, from their 
current oral antipsychotic to either a depot or different oral antipsychotic in this 
12-month, prospective observational study. Patients were compared on all-cause medi-
cation discontinuation rates, deﬁ ned as a switch from the initiated medication or its 
augmentation with another antipsychotic. Patients initiated on depot were matched 
with those initiated on any oral antipsychotic, using full optimal and nearest neighbour 
(greedy) matching algorithms. The Rank-based Mahalanobis metric was chosen as the 
distance based on propensity score plus other relevant covariates, with country and 
antipsychotic class used for exact matching. RESULTS: Based on the full optimal 1:1 
matching, only 40 of the 43 original depot initiators were matched to a corresponding 
oral initiator. After matching, there were no statistically signiﬁ cant differences between 
the depot and oral cohorts on any of the study entry covariates examined. During the 
12-month study, 20% of depot patients discontinued their initial medication, com-
pared with 40% of oral patients (survival curve comparison, p = 0.025; Hazard Ratio 
= 0.33 [0.12, 0.92], p = 0.033, NNT = 6 [3,-34]). No statistically signiﬁ cant differences 
were found between the two groups on other assessed outcomes, including hospitaliza-
tion, length of stay, and quality of life and disease severity measures. CONCLUSIONS: 
Systematic matching of patients initiated on depot with those initiated on oral anti-
psychotics showed that the oral-initiated patients were statistically signiﬁ cantly more 
likely to discontinue their medication. Findings highlight the importance of systematic 
matching of patient cohorts when comparing treatment outcomes in observational 
studies.
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OBJECTIVES: Hospital admission is a common and costly event in schizophrenia. An 
analysis of phase 1/1A CATIE clinical trial data assessed various patient socio-demo-
graphic and clinical characteristics in relation to risk of psychiatric hospital admission. 
METHODS: We followed 1460 study participants from baseline until ﬁ rst schizophre-
nia-related hospital admission, study medication discontinuation, or 18 months. Step-
wise Cox regression models assessed the adjusted hazard ratio (AHR) of hospital 
admission by baseline patient socio-demographic and clinical characteristics. 
RESULTS: In 869 person-years of follow-up, 203 patients were hospitalized. The adjusted 
hazards of hospital admission were not signiﬁ cantly related to patient socio-demographic 
characteristics. Increased risk of admission was linked to early age (<17 years) of ﬁ rst 
antipsychotic treatment (AHR: 2.09; 95%CI: 1.45–3.02), psychiatric hospital admission 
in past year (AHR: 2.92; 95%CI: 2.18–3.90), and DSM-IV alcohol (AHR: 1.55; 95%CI: 
1.15–2.08) and drug (AHR: 1.50; 95%CI: 1.13–2.00) use disorders in the past 5 years. 
Severe (5–7) as compared with mild (1–3) baseline global clinical severity (AHR: 1.51; 
95%CI: 1.03–2.23) (CGI-I), high (>20) as compared with low (7–15) positive symptoms 
(AHR: 1.53; 95%CI: 1.08–2.16) (PANSS-positive subscale), and low (0–2.2) as compared 
with high (>3.1) social function (AHR: 1.47; 95%CI: 1.04–2.08) (Heinrichs-Carpenter 
QLI) were related to signiﬁ cantly increased risk of hospital admission. As compared with 
olanzapine treatment assignment, quetiapine (AHR: 2.12; 95%CI: 1.37–3.27), perphen-
azine (AHR: 1.64; 95%CI: 1.02–2.65), and ziprasidone (AHR: 2.67; 95%CI: 1.62–4.39), 
though not risperidone (AHR: 1.40; 95%CI: 0.89–2.21), were also associated with 
increased hospital admission risk. Self-rated physical health (SF-12 PCS) and drug attitudes 
(DAI) were not signiﬁ cantly related to risk. CONCLUSIONS: In the treatment of schizo-
phrenia, efforts to lower hospital admission risk should focus on patients with early 
onset disorders, recent inpatient admissions, severe positive symptoms, high global 
clinical severity, poor social function, and comorbid substance use disorders and should 
select an appropriate antipsychotic medication.
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A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE 
EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE 
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OBJECTIVES: To assess the efﬁ cacy of a 600 mg/day dose of Quetiapine Extended 
Release administrated once a day at evening as monotherapy or in combination with 
lithium or valproate for 21 days. METHODS: A multi-center phase IV study was 
designed to assess the efﬁ cacy of quetiapine extended release 600 mg per day either 
as monotherapy or combined therapy with lithium and valproic acid in the treatment 
